论文信息 - First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases - 字舞流文

First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases

E. Healy | R. Allen | Mark M. Jones | D. Tytgat | E. Jones | A. Koch | Mark I L Watling | E. Helmer | A. Payne